title: Oral propranolol decreases intestinal permeability in patients with cirrhosis: another protective mechanism against bleeding?
authors: Marco
authors: M
authors: Senzolo
authors: W
authors: W
authors: Fries
authors: A
authors: A
authors: Buda
authors: D
authors: D
authors: Pizzuti
authors: E
authors: E
authors: Nadal
authors: G C
authors: GC
authors: Sturniolo
authors: A K
authors: AK
authors: Burroughs
authors: R
authors: R
authors: D'Incà
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D018988:Bacterial Translocation / Q000187:drug effects; D002986:Clinical Trials as Topic; D004932:Esophageal and Gastric Varices / Q000150:complications*; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control*; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D008103:Liver Cirrhosis / Q000150:complications*; D010538:Peritonitis / Q000517:prevention & control*; D011433:Propranolol / Q000627:therapeutic use*
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol